antibody, produced from a pure single-cell culture line. Their availability had a major impact on the development of immunology, and on technological and commercial developments.
The meeting was introduced by Dr Robert Bud, Head of Life and Environmental Sciences at the Science Museum, who remarked that, whilst contemporary history offers a rare interaction between subject and viewer, the relationship can be as daunting as it is exciting. But, he emphasized, that relationship provides an opportunity for us to have a much more interesting interchange and identification of what are already understood to be momentous and important changes and developments. Already it is clear that the emergence of biotechnology as a whole is one of the big shifts in late twentieth century technology.
The term "new biotechnology" had been popularised by the 1984 Office of Technology Assessment Report, Commercial Biotechnology, and this "new biotechnology" stood on three legs. One, which had quickly been forgotten, comprised new fermentation technologies. The other two, much better known, were recombinant DNA and hybridoma, specifically monoclonal antibody, technology.
Bud then examined the contexts of the monoclonal antibody story. Firstly, the tissue culture work with myelomas and techniques of cell fusion had all been in use in Cesar Milstein's laboratory in the Medical Research Council's Laboratory of Molecular Biology in Cambridge, one of the world's premier bio-medical research Institutes. When the significance of the achievement was recognized, in the 1980s, questions had immediately been raised as to who had done the work, typifing the complexities of real scientific discoveries, which are often difficult to explain to the public. Milstein also wondered whether the applications of the hybridoma technology had been clear in their own minds, or in others' at the time of the discovery. When he and Kohler had been writing the original paper and considering the final sentence, they had been hesitant in emphasizing the potential. After much discussion, they had included the remark because they were convinced that the technique would prove valuable, although he continued, I am not saying that we discussed how many zeroes it would be worth at the end of the equation. I confess I would never have dreamt the number of zeroes that actually appeared, probably neither did Georges.
The scientific background of the work was recalled by Professor Kohler, who had moved to Milstein's lab as a young post-doctoral fellow, having completed a PhD on antibody heterogeneity at Basle. The mid-I1970s was a period when several ideas about antibody generation were prominent, especially the "somatic mutation" theory promoted by Niels Jerne, and the more conventional "germline" hypothesis. Milstein's lab was experienced in studying myelomas, tumours of the immune system, in mice. Using a technique developed earlier by Potter, they had established a culture of rapidly proliferating tumour cells that produced immunoglobulins or antibodies. With Dick Cotton, Milstein had examined the structure of immunoglobulins, which are composed of four chains: 2 heavy chains which, like the upright of the letter "Y", constitute the antibody's constant region and two light chains, which in association with terminal parts of the heavy chains, like the extended arms of the letter "Y", form the variable region of the immunoglobin. Using rat/mouse hybrid myelomas, Milstein and Cotton had shown that the regions of the immunoglobulin were always of one species, although the chains could be hybrids of both.
The reputation of, and techniques available in, Milstein's lab had drawn Kohler to Cambridge.
It was the story of a young scientist looking for a good laboratory, which was exactly what I found in Cesar Milstein's laboratory. He was working with myeloma P3 which were growing in culture and had produced the first mutants. I was fascinated by the idea that you could generate a diversity of antibody specificities by starting with one gene and diversifying it by mutation.
The technical problem, however, was that myelomas produced antibodies of unknown specificity. Milstein suggested that Kohler should investigate the antigen specificity of his myeloma P3 antibodies. Instead, Kohler turned the problem around, trying to generate antibodies with defined specificity. Thus, instead of fusing two myelomas, he decided to fuse one with an antibody-producing cell, a B-lymphocyte. Milstein, Kohler stressed, was prepared to listen. "He did not dismiss it as out of reach, the strange idea of a post-doc, but he sat down and we discussed the possibilities."
Kohler decided to fuse mouse spleen cells, which are rich in B lymphocytes, with mouse myeloma cells. Although a rare product of the fusion technique the resulting hybrid cell, or hybridoma, was extremely important. By raising the levels of antibody through pre-immunization, and then fusing the spleen and myeloma cells, the hybridoma combined two attributes: the long-living properties of the myeloma, and the specificity of the antibody. For the first time, then, large quantities of a pure, specified antibody could be produced. The first experiment succeeded, Kohler remarking laconically, "We thought we should make a hybrid, and so I did the fusion, and it worked out very nicely".
This discovery revolutionized the study of immunity and the immune response, and generated clinical applications. These developments, for which Kohler and Milstein's discovery was freely available, later led to much debate, discussion and recrimination about the absence of patent protection, an aspect which was discussed by Dr David Secher, a contemporary of Milstein and Kohler in Cambridge, and later the lab's first industrial liaison officer, and Dr David Owen, the current director of industrial collaboration of the MRC.
The scientific aspects were discussed by Sir James Gowans, the distinguished immunologist and subsequently, in 1977, the Secretary of the MRC, who recalled the impact of the first announcement of the work. I don't remember being shattered. I think I was actually at the first meeting where Cesar talked about his results and I remember being mightily intrigued. I thought it was extremely ingenious and very interesting and one went away and talked about it and told one's friends what Cesar had been up to. Some time later when the commercial possibilities became clear, I remember thinking back to the days when I listened to the lecture. One was not thinking at the time when one was in the lecture that there was a vast catalogue of diagnostic reagents just waiting on the horizon, or perhaps even therapy. These possibilities were certainly not mentioned in the lecture. It was a very interesting, biologically-illuminating bit of science, but also a method for producing very pure antibodies, which of course one could see would be important for research. It was a beautiful piece of science. The media often presents science as a mixture of breakthroughs and disasters but it really doesn't work like that: science is usually a slow chipping away and every now and again there is a big chip and this was a big chip which we all sat up and took notice of.
Another eminent immunologist Ita Askonas, commented, I remember the excitement, although the report of the first antigen specific hybridoma was not shattering. It was not the first time that people thought about trying to do cell-cell fusions, but this was the first time it was successful. The only real surprise was the fact that selection of hybridomas producing monoclonal antibodies worked so well and reproducibly. I have to admit and I think Cesar could tell this story too-that Alan Williamson and myself had been working some years before, attempting to get monoclonal antibodies by transferring B-cell clones in vivo. That worked well through quite a few transfer generations until suddenly the clones started to die-senescence.
We tried to fuse the clones with transformed cells, using Littlefield's method, but without success. Therefore I was absolutely thrilled to hear of the achievements of CUsar's laboratory.4
But, after the first successes, the next set of experiments went badly or failed completely. Kohler was appointed to the Institute of Immunology at Basle, but neither there nor in Cambridge would the experiments work. He and Milstein recalled hours on the telephone and the frequent exchange of serum and cell preparations, Milstein going on to comment, the reasons actually, probably were different in both cases, and in ours it was quite an unbelievable situation. We were using something called HAT medium, which is a medium specially for the selection of hybrids, and in preparation of this medium we kept it in concentrated form. Now, just before Georges left the lab the concentrated solution was finished and one of my students prepared a new solution, and this was a concentrated solution. From there dilutions were prepared here and there in several stages, and it transpired six months later it took us six months to find out-that that solution, for some reason which we never found out, was toxic, so instead of selecting cells we were killing them. That was certainly not the case in your [Kohler's] lab. I don't know why in your case, it must have been something like that.
The time-course for the success to become apparent was also emphasized by David Secher:
The first experiment worked, but then there were experiments that did not work, for reasons that were not obvious, and there was quite a long time when it did not work and so, with hindsight of course, there was not a single shattering moment when the paper was published. Of course, had it not turned out to be reproducible or had it not turned out that medicine and technology would be so important we would not now be looking back and talking about when was that single moment?
Many of the seminar participants emphasized that the invention of monoclonal antibodies relied on many factors: the availability of relevant techniques in an established laboratory; the conjunction of ajunior and a senior scientist with synergistic skills, interests and experience, enabling a new idea to be tried and developed; and the way in which scientific discoveries build and extend the work of previous generations. Several, especially the two Nobel Laureates themselves and David Secher, stressed the importance of pursuing and supporting basic research, and the particular value of the supportive ambience in the Laboratory of Molecular Biology.
Milstein's own career, from arriving at the LMB as a young Argentinian scientist, had benefited greatly from the lab's traditions. Employed to work with Fred Sanger, the proposed collaboration had not been successful, and Sanger encouraged and supported Milstein in pursuing his own ideas, "Do good experiments and don't worry about anything else", he told his young protege. No one had stopped him crossing disciplinary boundaries or developing new ideas. Milstein stressed that dedicated research institutes are critical for the development of good research, suggesting that "laziness is the mother of good science". In a teaching environment a scientist might be tempted, when faced with obstacles and difficulties, to devote more of his resources to teaching. But in a pure research environment, such as the LMB, a scientist had to think and think to get out of his impasse. And both Milstein and Kohler discussed the questions that arose from their collaboration. Did one make a more substantial contribution than the other? Kohler, remembering his arrival in Cambridge, cited the ease of communicating with Milstein as one of the attractions of the lab. Milstein agreed that this was a major reason for accepting the younger man into his lab, Why did I accept him? I had two candidates, and the reason I accepted him was because it was clear that there was something communicating in our minds. Somehow I felt that we were talking the same language.
Questions about the respective roles of the two scientists had become more explicit when they shared a Nobel Prize; they had prepared a joint statement to explain their collaboration.
We agree that both conception and execution of the work was the result of close collaboration between us, with the skilled technical assistance of Shirley Howe. We are further convinced that the combined effect which results from such close collaboration was of a synergistic nature, synergistic effects taken to mean, as with monoclonal antibodies, effects which result from the combined action of two but which cannot be produced by the two separately. We both have a most pleasant memory of an exciting period in which a word, a comment, or a passing remark made by one had a resonant effect on the other. We do not want such happy memories, which have sealed a close friendship, to be disturbed by superficial interpretations of our individual recollections. It was a collaborative work. It was a collaborative paper. We do not want to make further comments.
